Skip to content

CMS & Regulatory Compliance

Washington MHMDA

Washington MHMDA for Ambulatory & Telehealth

How ambulatory and telehealth clinics operationalize RCW 19.373 opt-in consent, non-sale boundaries, and RAM-only audio for AI documentation. Book your workflow audit at https://cal.com/merryai/demo.

Executive Key Takeaways

  • MHMDA (RCW 19.373) requires clear affirmative opt-in consent before any consumer health data is collected, and a separate distinct opt-in before that data is shared with an AI vendor
  • Physician attestation and consent-status logging must record time, consent version, and scope (collection vs. sharing vs. training) for every ambulatory and telehealth encounter
  • Validated consent-gating and disclosure prompts are available through the templates.scribing.io directory to align verbal scripts with the statutory disclosure checklist
Regulatory Verification Framework
2026 Audit Ready
RCW 19.373 §.030Verified Compliant

Opt-In Collection Consent

Opt-In Collection Consent

RCW 19.373 §.040Verified Compliant

Separate Sharing Consent

Separate Sharing Consent

RCW 19.373 §.090Verified Compliant

No Sale Without Valid Authorization

No Sale Without Valid Authorization

CA AB 3030Verified Compliant

Patient Notice Parity

Patient Notice Parity

Why Washington's MHMDA Reaches Every Ambulatory and Telehealth Note

Washington's My Health My Data Act (RCW 19.373) imposes one of the strictest consumer health data regimes in the United States, and its reach extends well beyond the boundaries that clinicians typically associate with HIPAA. The Act applies to any regulated entity that conducts business in Washington or targets Washington consumers and determines the purpose and means of collecting, processing, sharing, or selling consumer health data. For an ambulatory clinic or telehealth practice, this means the statute governs any system that captures, transcribes, or analyzes patient audio, video, notes, or session metadata.

Consumer health data under the statute is defined expansively as any personal data that identifies or is reasonably linkable to a consumer and that is used to infer physical or mental health, diagnosis, treatment, or health-related behaviors. Critically, the definition captures non-HIPAA settings, including direct-to-consumer health applications, telehealth platforms operating on non-covered infrastructure, and audio-only encounters. When an AI documentation tool listens to a visit, it is processing consumer health data by definition, and the full weight of the opt-in framework attaches to that processing.

Practices frequently assume that HIPAA compliance confers MHMDA compliance, and that assumption is a documented source of enforcement exposure. HIPAA operates on a permission-and-minimum-necessary model; MHMDA operates on an affirmative opt-in model closer to GDPR. A clinic can be fully HIPAA-conformant and still violate RCW 19.373 by collecting scribe audio without the clear affirmative act the Act demands. When referencing the underlying statutory codes and the peer-reviewed literature on state health-privacy divergence, the archive at PubMed Central is a useful primary anchor for informatics teams building their governance record.

MHMDA's consent standard is deliberately demanding, requiring a clear affirmative act that is freely given, specific, informed, opt-in, voluntary, and unambiguous. Passive notice, pre-checked boxes, and opt-out mechanics all fail this standard. Beginning March 31, 2024, a regulated entity may not collect consumer health data except with opt-in consent for a specified purpose, or when collection is strictly necessary to provide a product or service the consumer requested. For AI scribing, explicit consent is the defensible path.

The statute separates collection from sharing in a way that trips up most generic deployments. Section .030 governs the initial capture; Section .040 requires a separate and distinct opt-in before that data is shared with any third party. Because a cloud-based scribe vendor is a distinct entity from the clinic, transmitting session audio to that vendor is a sharing event requiring its own affirmative authorization. A single consolidated consent prompt does not satisfy both obligations, and stitching them together is a common defect we intentionally prevent.

Effective consent gating operationalizes the disclosure checklist rather than treating it as boilerplate. Before any audio enters the pipeline, the workflow must disclose the categories of data collected, the specific clinical purpose, the categories of recipients, whether any secondary use is contemplated, and how the patient may decline while still receiving care. The affirmative act itself can be a recorded verbal 'Yes, I agree' or an electronic acknowledgment, but it must be captured and logged before the microphone stream opens. Validated consent scripts and disclosure templates that map directly to the statutory elements are maintained in the Scribing Template Directory, which practices can adapt to their intake language.

Documenting the Encounter Under Telemedicine Rules

Washington's Apple Health telemedicine guidance requires that telehealth notes capture the modality, whether audio-only or audio-video, the HIPAA-compliant platform used, the patient's physical location, the provider's location and credentials, any additional attendees, and the start and end times of the service. Layered atop these clinical fields, the record must also reflect MHMDA consent status: whether collection consent was obtained, whether sharing consent was obtained, the date and time, and the method. Merry AI emits these as structured events so the clinical note is populated without manual re-entry.

The Non-Sale Boundary and Its Practical Consequences

The Act's prohibition on selling consumer health data is among its sharpest provisions. Under Section .090, it is unlawful to sell or offer to sell consumer health data without first obtaining valid authorization, a bar considerably higher than ordinary consent and one that carries specific content and form requirements. There is no necessity exception for sale or for secondary uses; necessity applies only to collection and sharing required to deliver a requested service, never to monetization.

For any AI documentation vendor operating in Washington, this reshapes the permissible business model. Revenue must derive from subscription or licensing fees paid by clinics, not from brokering, reselling, or monetizing patient-derived data. Merry AI is architected and contracted as a non-broker and non-seller: no advertising-technology integrations, no profiling, and no resale of derived features. De-identified data receives no automatic pass, because data that remains reasonably re-linkable is still consumer health data within the statutory definition.

Configuring the Washington Deployment Profile

A defensible deployment isolates Washington-specific controls into a discrete configuration profile that clinics can point to during an audit. In that profile, audio is non-persisted by default and processed in volatile memory only; transient transcription buffers are destroyed on a zero-day schedule once the note is attested; and all model-training and analytics flags are disabled unless a separate, explicit authorization exists. Consent and session metadata logging is robust enough to reconstruct the compliance posture of any individual encounter on demand.

Comparing Documentation Architectures

The practical differences among documentation approaches become clearest when contrasted directly. Manual charting minimizes third-party data flow but consumes clinician time and produces inconsistent consent records. Generic AI scribes save time but frequently retain audio, bundle consent, and reserve broad training rights that MHMDA does not permit. A compliance-first architecture reconciles efficiency with the statutory mandate.

DimensionManual ChartingGeneric AI ScribeMerry AI Compliance Architecture
Consent modelAd hoc, often verbal onlySingle bundled checkboxSeparate opt-in for collection and sharing per RCW 19.373
Audio retentionNone capturedPersistent cloud storageRAM-only, zero-day buffer shredding
Data for model trainingNot applicableDefault enabled in termsDisabled absent separate valid authorization
Sale or brokering riskLowVariable, often opaqueContractually prohibited, subscription revenue only
Consent-status loggingInconsistentRarely encounter-levelTime, version, and scope logged per encounter
Physician attestationManual signatureDraft accepted silentlyExplicit attestation event tied to consent record

Physician attestation remains the anchor of medico-legal defensibility across every architecture. The clinician reviews the AI-generated draft, confirms no unconsented secondary use has occurred, and records an explicit attestation event that binds the finalized note to the underlying consent record. This attestation, combined with encounter-level consent logging and same-day buffer destruction, produces the evidentiary trail an enforcement inquiry examines first. Practices ready to align their intake scripts, consent architecture, and Washington deployment profile can Book a 15-Minute Workflow Audit to review their current posture against RCW 19.373 element by element.

Regulatory & Compliance FAQ

Does MHMDA require a separate opt-in for sharing audio with the AI scribe vendor, or is a single clinical consent enough?

RCW 19.373 draws a hard line between collection consent and sharing consent, and a single blanket clinical consent will not satisfy both. Section .030 requires opt-in consent for a specified purpose before consumer health data is collected, while Section .040 requires a separate and distinct opt-in before that same data is shared with any third party. When Merry AI operates as a processor distinct from the clinic, transmitting audio or transcript features to our infrastructure constitutes 'sharing' as defined in the Act. Our Washington deployment profile therefore presents two discrete affirmative acts: one authorizing capture for documentation, and one authorizing transmission to Merry AI, each disclosing the categories of data, the specific use, and the recipient. Bundling these into one checkbox is a documented compliance defect that we intentionally block at the workflow level.

If Merry AI processes audio only in volatile RAM and shreds buffers same-day, does that legally satisfy MHMDA even without patient consent?

No. MHMDA is technology-neutral and does not create a processing-architecture exemption, so RAM-only handling and zero-day shredding do not substitute for the opt-in consent mandate. What these controls do accomplish is materially reduce the scope of what is 'collected' and 'retained,' which strengthens data-minimization posture and makes non-sale representations credible. Raw audio is never written to persistent storage; only the finalized clinical note, under the provider's control, survives the session. Transient transcription artifacts held for error recovery are destroyed once the note is attested. Consent remains the gating legal control; the RAM architecture is the technical control that limits residual liability if a dispute later arises over secondary use. Both layers are required, not interchangeable.

When an AI scribe accidentally captures audio before consent is confirmed, who bears the medico-legal liability and what is the required remediation?

Under MHMDA the regulated entity, typically the clinic, retains primary responsibility for any collection that occurs without valid opt-in, and the vendor's data processing agreement allocates downstream obligations. Because consent under RCW 19.373 must be obtained prior to collection, a pre-consent capture is a collection defect requiring immediate remediation. Merry AI's architecture hard-gates the microphone stream: no audio enters the processing pipeline until the affirmative consent event is logged. In the event of a mis-fire, our incident playbook flags the encounter, purges any transient buffer, records the time and nature of the failure, and generates an entry the clinic can reference in its own breach-assessment log. The finalized note documents that no non-consented data was retained, which is the evidentiary record an enforcement inquiry would examine.

Can a patient withdraw MHMDA consent during a telehealth encounter, and how must the documentation reflect that?

Yes. MHMDA requires that the consent request disclose how a consumer may withdraw consent from future collection or sharing, and mid-session withdrawal must be honored. Operationally, when a patient revokes consent during an audio-video or audio-only encounter, the clinician deactivates the scribe, and the record must capture the exact time of withdrawal, the actions taken, and the disposition of any data already captured. Our system emits a structured withdrawal event that populates the clinic's telehealth note alongside the modality, participant, and location fields Washington's Apple Health telemedicine guidance already requires. Care continues; the clinician documents manually from that point forward. The critical evidentiary element is that data captured before withdrawal is either restricted to the finalized note or purged consistent with the original consent scope.

Is de-identified session data still regulated under MHMDA, and can Merry AI use it for model training?

MHMDA reaches any personal data reasonably linkable to a consumer, so de-identification is not an automatic escape hatch; data that can be re-linked remains consumer health data. There is no necessity exception for secondary uses or sale, meaning model training that exceeds what is strictly required to deliver the requested documentation service demands a separate, explicit opt-in that meets the Act's heightened standards. Our default Washington posture disables all training and product-analytics flags. We do not broker, license, or sell patient-derived data, consistent with the Attorney General's position that selling consumer health data without valid authorization is unlawful. If a clinic and patient wish to contribute to model improvement, that authorization is captured as a distinct, revocable event, never bundled into the documentation consent, and reviewed against the statutory definitions before any data leaves the clinical scope.

Explore More Knowledge

Related Clinical Rules & Compliance Guides

View all clinical rules & compliance
Florida Statute 934.03 Compliance for Psychiatry
CMS & Regulatory Compliance

Florida Statute 934.03 Compliance for Psychiatry

Enforce all-party verbal consent before psychiatric audio capture under Fla. Stat. 934.03(2)(d). Book your audit at https://cal.com/merryai/demo.

Dr. Sarah Chen, MD•7 min read
Read guide
Illinois 720 ILCS 5/14-2: Internal Medicine Consent
CMS & Regulatory Compliance

Illinois 720 ILCS 5/14-2: Internal Medicine Consent

Document all-party consent before ambient capture in Illinois internal medicine visits. Book your audit at https://cal.com/merryai/demo.

Dr. Sarah Chen, MD•7 min read
Read guide
Texas HB 149 AI Disclosure for Family Medicine
CMS & Regulatory Compliance

Texas HB 149 AI Disclosure for Family Medicine

Timestamp HB 149 disclosures before capture and protect G2211 integrity. Book your audit at https://cal.com/merryai/demo.

Dr. Sarah Chen, MD•7 min read
Read guide